Antibody and other protein therapeutics are a major focus in drug discovery pipelines today. A critical stage in biologics drug discovery and development is the selection and characterization of lead molecules from large libraries. These molecules need to be screened for binding specificity and functional activity. A screening criteria for such molecules is their affinity for the target, thereby warranting the need for analytical instruments capable of characterizing such molecules.
Access this whitepaper to learn more about how to:- Find the right characterization technique
- Use bio-layer interferometry to eliminate challenges
- Push past limitations in the lead selection and optimization process
